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Short Report: Treatment
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Abstract
Aims To examine whether high-dose statin therapy in Dutch European patients with Type 2 diabetes and dyslipidaemia
influenced variables of glycaemic control.
Methods The CORALL study, which was a 24-week, open-label, randomized, parallel-group, phase IIIb, multi-centre
study, was designed to compare the cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with
Type 2 diabetes. Fasting plasma glucose levels and HbA1c levels were collected at baseline and at 6 and 18 weeks.
Results Treatment with the highest dose of statins, i.e. atorvastatin 80 mg and rosuvastatin 40 mg at 18 weeks from
baseline, was associated with increase in HbA1c levels; baseline 57  11 mmol ⁄ l (7.4  1.0%) to 61  14 mmol ⁄mol
(7.7  1.3%) (range 5.0–11.9) for atorvastatin (P = 0.003) and from baseline 60  11 mmol ⁄mol (7.6  1.0%) to
63  13 mmol ⁄mol (7.9  1.2%) (range 5.7–12.3) for rosuvastatin (P < 0.001). Mean fasting plasma glucose increased
from baseline 8.7  2.4 mmol ⁄ l to 9.5  3.0 mmol ⁄ l upon treatment with atorvastatin 20 mg (P = 0.002) and
9.0  3.0 mmol ⁄ l after treatment with 80 mg (not significant compared with baseline). The mean fasting plasma glucose did
not change after treatment with rosuvastatin (9.1  2.7 mmol ⁄ l at baseline, 8.9  2.7 mmol ⁄ l with 10 mg,
9.4  2.9 mmol ⁄ l with 40 mg).
Conclusions Glycaemic control deteriorated in patients with diabetes following high-dose statin therapy. Future controlled
studies are needed to verify these findings and, if confirmed, determine whether such changes represent a true decline in
glycaemic control. Presently, it appears that, based on the overwhelming prospective trial data available, the preventive effect
of statin therapy supersedes that of the slight increase in HbA1c.
Diabet. Med. 29, 628–631 (2012)
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Introduction
3-Hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase inhibitors (statins) protect against cardiovascular disorders
such as coronary heart disease and ischaemic cerebrovascular
disease. Several large-scale studies have reported that high-risk
patients, for example those with existing cardiovascular disease
and Type 2 diabetes mellitus, show a considerable clinical
benefit from statin treatment, and clinical guidelines recommend
prescription of statins in such patients irrespective of baseline
serum cholesterol levels [1–4]. Statins have an acceptable safety
and tolerability profile [5].
However, recently a well-conducted meta-analysis of
randomized trials reported a 9% higher risk of development of
diabetes in statin users compared with placebo (odds
ratio 1.09; 95% CI 1.02–1.17) [6]. Furthermore, in a recently
published pooled analysis of data from five statin trials, high-
dose statin therapy was associated with a 12% more risk of
new-onset diabetes compared with moderate-dose statin ther-
apy [7]. High-dose atorvastatin treatment compared with
placebo in the Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial was even associated with a
44% increased risk of new-onset diabetes [8].
Deterioration of glycaemic control has been observed after
initiation of atorvastatin therapy in patients with Type 2
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diabetes mellitus in Japan [9,10]. In a retrospective study,
Takano et al. compared the effect of atorvastatin and pra-
vastatin on glycaemic control in people with diabetes [9].
HbA1c increased from 51  10 mmol ⁄mol (6.8  0.9%) to
55  12 mmol ⁄mol (7.2  1.1%) (P < 0.001) only in the
atorvastatin group after 3 months of treatment. Somewhat
similar findings have been observed in a prospective study in
people with diabetes as well as those without diabetes [12,13].
One of the mechanisms for the detrimental effects of statins on
glucose metabolism, at least of atorvastatin, could be the
decreased expression of insulin-sensitive solute carrier family 2
(facilitated glucose transporter), member 4 (SLC2A4, formerly
known as GLUT4) [10].
As part of the CORALL study [14], we examined whether
18 weeks of high-dose statin therapy in Dutch European
patients with Type 2 diabetes and dyslipidaemia influenced
variables of glycaemic control.
Research design and methods
The CORALL study was a 24-week, open-label, randomized,
parallel-group, phase IIIb, multi-centre study. The first 6 weeks
of the study was a dietary lead-in period, after the patients who
fulfilled all inclusion criteria and none of the exclusion criteria
were randomized to receive either rosuvastatin or atorvastatin.
The study was designed to compare the cholesterol-lowering
effects of rosuvastatin with atorvastatin in patients with Type 2
diabetes. Subjects were evaluated for efficacy on an intention-
to-treat analysis, which contained all randomized subjects with
known baseline data. A detailed description of the CORALL
study has been previously reported [14]. Four hundred and
sixteen subjects with dyslipidaemia and Type 2 diabetes mell-
itus were enrolled in the study; of those, 263 patients fulfilled
the entry criteria and were randomized to either rosuvastatin
(n = 131) or atorvastatin (n = 132). The patients were treated
with either rosuvastatin 10 mg or atorvastatin 20 mg for
6 weeks, followed by force titration to rosuvastatin 20 mg
(if initially on rosuvastatin 10 mg) or atorvastatin 40 mg (if
initially on atorvastatin 20 mg) for 6 weeks and, finally, for
another 6 weeks, the patients were treated with rosuvastatin
40 mg (if initially on rosuvastatin 20 mg) or atorvastatin
80 mg (if initially on atorvastatin 40 mg). Fasting plasma glu-
cose and HbA1c levels were collected at baseline and at 6 and
18 weeks. HbA1c was measured in a central laboratory by
high-performance liquid chromatography (Bio-Rad Variant II
Automated Glycosylated Hemoglobin Analyzer; Bio-Rad
Laboratories, Hemel Hempstead, UK) with a normal range
26–44 mmol ⁄mol (4.5–6.2%). Plasma glucose levels were
analysed by the hospitals’ central laboratories, with normal
reference range as measured by high-performance liquid chro-
matography, and plasma glucose measured by the hexokinase
method.
Statistical analysis
spss version 16.0 (spss Inc., Chicago, IL, USA) was used for
statistical analysis. Data are given as mean  sd. The statistical
analysis of the data was carried out with the paired results
obtained at baseline and at 6 weeks and 18 weeks after initi-
ation of rosuvastatin or atorvastatin medication using the
Wilcoxon matched-pairs signed-ranks test and repeated mea-
sures analysis of variance (anova). P-values below 0.05 were
considered statistically significant.
Results
Table 1depicts thebaselinecharacteristics,with typical age,BMI
and blood pressure distribution for this population. No signifi-
cant change in body weight was observed during the study (data
not shown). The percentage of patients reaching target LDL
cholesterol values of < 2.5 mmol ⁄L (European Atherosclerosis
Society guideline) was 77.7, 83.1 and 90.0% with rosuvastatin
after 6 weeks (10 mg), 12 weeks (20 mg) and 18 weeks
(40 mg), respectively, whereas this goal was reached by 70.5,









Gender (men ⁄women) 59 ⁄ 72 63 ⁄ 69 122 ⁄ 141
Age (years) 61  9 59  10 60  10
BMI (kg ⁄m2) 31.8  6.1 31.0  6.0 31.4  6.1
Systolic blood pressure (mmHg) 145  20 148  17 147  19
Diastolic blood pressure (mmHg 82  8 83  8 83  8






Mean fasting plasma glucose (mmol ⁄ l) 9.1  2.7 8.7  2.4 8.9  2.6
Diet only 3 (2) 2 (2) 5 (2)
Oral blood glucose-lowering agents 40 (31) 47 (35) 87 (33)
Insulin 88 (67) 83 (63) 171 (65)
Hypertension 79 (60) 86 (65) 165 (63)
Baseline data are mean  sd or absolute number (%). There were no significant differences between both treatment groups.
DIABETICMedicineOriginal article
ª 2011 The Authors.
Diabetic Medicine ª 2011 Diabetes UK 629
76.5 and 78.0% with atorvastatin after 6 weeks (20 mg),
12 weeks (40 mg) and 16 weeks (80 mg), respectively.
Six weeks’ treatment with atorvastatin 20 mg or rosuvastatin
10 mg did not change the HbA1c levels significantly [HbA1c
levels of 58  12 mmol ⁄mol (7.5  1.1%) in both treatment
groups) as compared with baseline [HbA1c 60  11 mmol ⁄mol
(7.6  1.0%) for rosuvastatin and 57  11 mmol ⁄mol
(7.4  1.0%) for atorvastatin, respectively] (Fig. 1). However,
treatmentwith the highest dose of statins, i.e. atorvastatin 80 mg
and rosuvastatin 40 mg at 18 weeks from baseline was associ-
ated with statistically significant increase in HbA1c levels:
61  14 mmol ⁄mol (7.7  1.3%) [range 31–107 mmol ⁄mol
(5.0–11.9%)] for atorvastatin (P = 0.003) and 63 
13 mmol ⁄mol (7.9  1.2%) [range 39–111 mmol ⁄mol (5.7–
12.3%)] for rosuvastatin (P < 0.001), respectively, as compared
with baseline (Fig. 1). The change in LDL cholesterol andHbA1c
were not related.
Mean fasting plasma glucose increased from baseline
8.7  2.4 to 9.5  3.0 mmol ⁄ l upon treatment with atorvast-
atin 20 mg (P = 0.002) and 9.0  3.0 mmol ⁄ l after treatment
with 80 mg atorvastatin (not significant compared with base-
line). The mean fasting plasma glucose did not change signifi-
cantly after treatment with rosuvastatin (9.1  2.7 mmol ⁄ l
at baseline, 8.9  2.7 mmol ⁄ l with rosuvastatin 10 mg,
9.4  2.9 mmol ⁄ l with rosuvastatin 40 mg).
Discussion
Among Dutch Caucasian patients with dyslipidaemia and
Type 2 diabetes, we found that (high-dose) statin therapy leads
to a small but significant increase of HbA1c levels.
Caucasian patients with Type 2 diabetes mellitus have been
included in many statin studies, but the effect of statin therapy
on glycaemic control has only been scarcely reported. In the
Collaborative Atorvastatin Diabetes Study (CARDS) the
patients with Type 2 diabetes treated with atorvastatin 10 mg
over 4 years had a mean HbA1c of 67 mmol ⁄mol (8.3%) [at
baseline 63  15 mmol ⁄mol (7.87  1.42%)] and the patients
on placebo had a mean of 65 mmol ⁄mol (8.1%) [at baseline
62  15 mmol ⁄mol (7.81  1.39%)] [1]. These results should
be interpreted with care, because the glycaemic control vari-
ables refers to only those patients who reached the 4-year point.
This might either under- or overstate any effect of atorvastatin
on glycaemic control. Although the initial dose of atorvastatin
therapy was higher in our study (20 mg), no change in HbA1c
levels as compared with baseline was observed. It may be that
the relatively short time course (6 weeks) of initial atorvastatin
therapy was the reason for the difference with CARDS,
although it cannot be excluded that there are dose–response
effects. A randomized, double-blind, double-dummy, multi-
centre, phase IIIb, parallel-group study to compare the efficacy
and safety of rosuvastatin (10 mg and 20 mg) and atorvastatin
(10 mg and 20 mg) in patients with Type 2 diabetes mellitus
(ANDROMEDA) study, the mean HbA1c increased from
52 mmol ⁄mol (6.9%) at baseline to 56 mmol ⁄mol (7.3%) at
week 16 with rosuvastatin 20 mg ⁄day, and from 53 mmol ⁄
mol (7.0%) at baseline to 56 mmol ⁄mol (7.3%) at week 16
with atorvastatin 20 mg ⁄day [13]. The difference with our
study is that, in ANDROMEDA, the statin therapy was given
at a fixed dose during a fixed time course.
In the Atorvastatin in Factorial with Omega-3 EE90 Risk
Reduction in Diabetes (AFORRD) study, an increase in HbA1c
of 1.5 mmol ⁄mol (0.3%) (P < 0.0001) after atorvastatin
(20 mg ⁄day) intervention, but no significant change in the
Omega-3 EE90 (2 g ⁄day) intervention after 4 months [14].
There are a few limitations to this study that need to be
addressed. The most important limitations are that we did not
have a placebo-control arm and the relatively short duration of
this study. Furthermore, this study was not powered to find a
difference in the glycaemic control. In addition, it may be
questioned whether the HbA1c increase is a real consequence of
worsening of glycaemic control, as neither CARDS nor
ANDROMEDA reported an increase in dose of blood glucose-
lowering agents, which may be the case when doctors or par-
ticipating patients witness an increase in blood glucose levels.
In conclusion, this short-term study of intensive statin therapy
in patients with diabetes suggests a small but significant increase
of HbA1c in statin recipients. Future controlled studies are nee-
ded to verify these findings and, if confirmed, determine whether
such changes represent a true decline in glycaemic control, or
some other mechanism perhaps linked to reduced oxidative
potential. Furthermore, whether this change remains in the
longer term, and has long-term implications, needs to be studied
before making any judgment on clinical relevance of these
observations. Presently, it appears that, based on the over-
whelmingprospective trial data available, the preventive effect of
statin therapy supersedes that of the slight increase in HbA1c.
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